Last reviewed · How we verify
BMS-986165
BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases.
BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases. Used for Psoriasis, Psoriatic arthritis, Crohn's disease.
At a glance
| Generic name | BMS-986165 |
|---|---|
| Also known as | Deucravacitinib |
| Sponsor | Bristol-Myers Squibb |
| Drug class | IL-12/IL-23 inhibitor |
| Target | IL-12/IL-23 p40 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The drug blocks the common p40 subunit shared by IL-12 and IL-23 cytokines, which are key drivers of Th1 and Th17 cell differentiation and inflammatory responses. By inhibiting both pathways simultaneously, BMS-986165 suppresses pathogenic immune responses implicated in autoimmune and inflammatory conditions. This dual inhibition provides broader immunomodulation compared to selective IL-23 inhibitors alone.
Approved indications
- Psoriasis
- Psoriatic arthritis
- Crohn's disease
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Headache
- Diarrhea
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus (PHASE2)
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (PHASE2)
- A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (PHASE3)
- A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 (PHASE4)
- Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris (PHASE2)
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |